首页> 外文期刊>Cell stem cell >NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia
【24h】

NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia

机译:NHEJ介导的CRISPR-CAS9诱导的DNA修复在患有FANCONI贫血患者中有效地纠正HSPC中的突变

获取原文
获取原文并翻译 | 示例
       

摘要

Non-homologous end-joining (NHEJ) is the preferred mechanism used by hematopoietic stem cells (HSCs) to repair double-stranded DNA breaks and is particularly increased in cells deficient in the Fanconi anemia (FA) pathway. Here, we show feasible correction of compromised functional phenotypes in hematopoietic cells from multiple FA complementation groups, including FA-A, FA-C, FA-D1, and FA-D2. NHEJ-mediated repair of targeted CRISPR-Cas9-induced DNA breaks generated compensatory insertions and deletions that restore the coding frame of the mutated gene. NHEJ-mediated editing efficacy was initially verified in FA lymphoblastic cell lines and then in primary FA patient-derived CD34(+) cells, which showed marked proliferative advantage and phenotypic correction both in vitro and after transplantation. Importantly, and in contrast to homologous directed repair, NHEJ efficiently targeted primitive human HSCs, indicating that NHEJ editing approaches may constitute a sound alternative for editing self-renewing human HSCs and consequently for treatment of FA and other monogenic diseases affecting the hematopoietic system.
机译:非同源末端连接(NHEJ)是造血干细胞(HSC)修复双链DNA断裂的首选机制,尤其是在范科尼贫血(FA)途径缺陷的细胞中增加。在这里,我们展示了对来自多个FA互补组(包括FA-A、FA-C、FA-D1和FA-D2)的造血细胞中受损功能表型的可行纠正。NHEJ介导的靶向CRISPR-Cas9诱导的DNA断裂修复产生代偿性插入和缺失,恢复突变基因的编码框架。NHEJ介导的编辑效应最初在FA淋巴母细胞系中得到验证,然后在原代FA患者来源的CD34(+)细胞中得到验证,这在体外和移植后都显示出显著的增殖优势和表型校正。重要的是,与同源定向修复相比,NHEJ有效地针对原始人类HSC,这表明NHEJ编辑方法可能是编辑自我更新的人类HSC,从而治疗FA和其他影响造血系统的单基因疾病的良好替代方法。

著录项

  • 来源
    《Cell stem cell》 |2019年第5期|共22页
  • 作者单位

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

    Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid 28040 Spain;

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

    Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid 28040 Spain;

    Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid 28040 Spain;

    Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid 28040 Spain;

    Hosp Santa Creu &

    Sant Pau Serv Genet Barcelona 08025 Spain;

    Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid 28040 Spain;

    Heinrich Heine Univ Dept Otorhinolaryngol &

    Head Neck Surg D-40225 Dusseldorf Germany;

    Hosp Univ Nino Jesus Madrid 28009 Spain;

    CNIO Mol Cytogenet Grp Human Canc Genet Program Madrid 28029 Spain;

    CNIO Mol Cytogenet Grp Human Canc Genet Program Madrid 28029 Spain;

    Ctr Invest Biomed Red Enfermedades Raras CIBERER Madrid 28040 Spain;

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

    Ctr Invest Energet Medioambientales &

    Tecnol CIEM Div Hematopoiet Innovat Therapies Madrid 28040;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号